A study assessing the effects of CX1739 on opioid induced respiratory depression in post-surgical patients self-administering opioids in a hospital setting.
Phase of Trial: Phase IV
Latest Information Update: 23 Dec 2016
At a glance
- Drugs CX 1739 (Primary)
- Indications Respiratory insufficiency
- Focus Therapeutic Use
- 23 Dec 2016 New trial record